You are here

Updated Label for NovoSeven Highlights Increased Risk of Arterial Thromboembolic Events

December 1, 2005 -- ROCKVILLE, MD -- Novo Nordisk and FDA notified healthcare professionals of revisions to the Warnings and Adverse Reactions sections of the prescribing information for NovoSeven, to provide updated safety information on thrombotic and thromboembolic adverse events, based on clinical studies in non-hemophilia patients and on post-marketing safety surveillance. A clinical study in elderly, non-hemophiliac, intracerebral hemorrhage patients indicated a potential increased risk of arterial thromboembolic adverse events with use of NovoSeven, including myocardial ischemia, myocardial infarction, cerebral ischemia and/or infarction.

Read the complete MedWatch 2005 Safety summary, including links to the "Dear Healthcare Professional" letter and revised prescribing information, at:

Source: The Food and Drug Administration

Recent Headlines

Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Artificial Intelligence Enables Platform to Detect Amyloid PET Status
Kadcyla Cut Risk of Recurring Disease by Half Compared to Herceptin
May Lead to Personalized Treatment for Schizophrenia, Other Illnesses
Rare Disorder Typically Co-occurs With Cancer